Pfizer abandons twice-daily GLP-1 approach due to high discontinuation rates, goes back to PhI with once-a-day dose

Pfizer won’t be moving a twice-daily formulation of its oral GLP-1, danuglipron, into Phase III after the drug triggered high rates of side effects, despite meeting the primary endpoint of its mid-stage weight loss trial. […]